SI4331584T1 - Terapevtske uporabe devteriranih derivatov lanifibranorja - Google Patents
Terapevtske uporabe devteriranih derivatov lanifibranorjaInfo
- Publication number
- SI4331584T1 SI4331584T1 SI201930912T SI201930912T SI4331584T1 SI 4331584 T1 SI4331584 T1 SI 4331584T1 SI 201930912 T SI201930912 T SI 201930912T SI 201930912 T SI201930912 T SI 201930912T SI 4331584 T1 SI4331584 T1 SI 4331584T1
- Authority
- SI
- Slovenia
- Prior art keywords
- lanifibranor
- therapeutic uses
- deuterated derivatives
- deuterated
- derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1857021A FR3084254B1 (fr) | 2018-07-27 | 2018-07-27 | Derives deuteres du lanifibranor |
| EP23201458.9A EP4331584B1 (fr) | 2018-07-27 | 2019-07-26 | Utilisations thérapeutiques de dérivés deutérés du lanifibranor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI4331584T1 true SI4331584T1 (sl) | 2025-04-30 |
Family
ID=63684156
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930912T SI4331584T1 (sl) | 2018-07-27 | 2019-07-26 | Terapevtske uporabe devteriranih derivatov lanifibranorja |
| SI201930700T SI3830085T1 (sl) | 2018-07-27 | 2019-07-26 | Devterirani derivati lanifibranorja |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930700T SI3830085T1 (sl) | 2018-07-27 | 2019-07-26 | Devterirani derivati lanifibranorja |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12291526B2 (sl) |
| EP (2) | EP3830085B1 (sl) |
| JP (2) | JP7434278B2 (sl) |
| CN (1) | CN112638911B (sl) |
| DK (2) | DK4331584T3 (sl) |
| ES (2) | ES3014955T3 (sl) |
| FI (2) | FI4331584T3 (sl) |
| FR (1) | FR3084254B1 (sl) |
| HR (2) | HRP20250340T8 (sl) |
| HU (2) | HUE065045T2 (sl) |
| LT (2) | LT3830085T (sl) |
| MA (1) | MA67726B1 (sl) |
| MD (1) | MD4331584T2 (sl) |
| PL (2) | PL3830085T3 (sl) |
| PT (2) | PT4331584T (sl) |
| RS (2) | RS65095B1 (sl) |
| SI (2) | SI4331584T1 (sl) |
| SM (2) | SMT202500113T1 (sl) |
| WO (1) | WO2020021215A1 (sl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102199640B1 (ko) * | 2020-01-06 | 2021-01-07 | 브렉소젠 주식회사 | 라니피브라노르를 포함하는 줄기세포 유래 엑소좀 생성 촉진 및 줄기세포기능 강화용 조성물 |
| EP4000616A1 (en) * | 2020-11-17 | 2022-05-25 | Inventiva | Combination therapy for the treatment of a liver disease |
| WO2022143479A1 (zh) * | 2020-12-29 | 2022-07-07 | 广东东阳光药业有限公司 | 一种化合物的固体形式及其制备方法和用途 |
| MX2024001745A (es) * | 2021-08-12 | 2024-04-10 | Crystal Pharmaceutical Suzhou Co Ltd | Forma cristalina de lanifibranor, método de preparación del mismo y su uso. |
| IL322148A (en) | 2023-01-19 | 2025-09-01 | Inventiva | Formulation of Lenifibernor |
| WO2024251730A1 (en) | 2023-06-05 | 2024-12-12 | Inventiva | Lanifibranor for use in the treatment of splanchnic vasodilatation in a patient with a liver condition |
| AU2023451557A1 (en) | 2023-06-06 | 2026-01-15 | Inventiva | Use of adiponectin, ferritin, mmp9 and transferrin for monitoring liver disease treatment with lanifibranor |
| AU2023451460A1 (en) | 2023-06-06 | 2026-01-15 | Inventiva | Use of ck18m65, hyaluronic acid, fructosamine and alt for monitoring of liver disease treatment with lanifibranor |
| TW202519213A (zh) | 2023-09-22 | 2025-05-16 | 法商因文帝華公司 | 蘭尼菲諾(lanifibranor)之製造方法 |
| WO2025132989A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025132955A1 (en) | 2023-12-21 | 2025-06-26 | Inventiva | Combination therapy for the prevention and/or the treatment of a liver disease |
| WO2025191292A1 (en) | 2024-03-15 | 2025-09-18 | Inventiva | Methods and monitoring of treatment with lanifibranor |
| TW202543596A (zh) | 2024-03-15 | 2025-11-16 | 法商因文帝華公司 | 預防接受過氧化物酶體增生劑活化受體（ppar）促效劑治療患者之血液病症 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2890071B1 (fr) * | 2005-08-30 | 2007-11-09 | Fournier Sa Sa Lab | Nouveaux composes de l'indole |
| MX373268B (es) | 2014-06-13 | 2020-04-16 | Inventiva | Compuestos ppar para uso en el tratamiento de enfermedades fibroticas. |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| WO2018039521A1 (en) | 2016-08-26 | 2018-03-01 | Concert Pharmaceuticals, Inc. | Deuterated cenicriviroc |
| US11504380B2 (en) * | 2019-11-08 | 2022-11-22 | Inventiva | Method of treatment of cirrhosis |
-
2018
- 2018-07-27 FR FR1857021A patent/FR3084254B1/fr active Active
-
2019
- 2019-07-26 PT PT232014589T patent/PT4331584T/pt unknown
- 2019-07-26 JP JP2021504431A patent/JP7434278B2/ja active Active
- 2019-07-26 HU HUE19759658A patent/HUE065045T2/hu unknown
- 2019-07-26 CN CN201980049453.4A patent/CN112638911B/zh active Active
- 2019-07-26 HU HUE23201458A patent/HUE070489T2/hu unknown
- 2019-07-26 US US17/261,938 patent/US12291526B2/en active Active
- 2019-07-26 MA MA67726A patent/MA67726B1/fr unknown
- 2019-07-26 LT LTEPPCT/FR2019/051860T patent/LT3830085T/lt unknown
- 2019-07-26 PL PL19759658.8T patent/PL3830085T3/pl unknown
- 2019-07-26 PT PT197596588T patent/PT3830085T/pt unknown
- 2019-07-26 EP EP19759658.8A patent/EP3830085B1/fr active Active
- 2019-07-26 FI FIEP23201458.9T patent/FI4331584T3/fi active
- 2019-07-26 WO PCT/FR2019/051860 patent/WO2020021215A1/fr not_active Ceased
- 2019-07-26 SM SM20250113T patent/SMT202500113T1/it unknown
- 2019-07-26 EP EP23201458.9A patent/EP4331584B1/fr active Active
- 2019-07-26 HR HRP20250340TT patent/HRP20250340T8/hr unknown
- 2019-07-26 FI FIEP19759658.8T patent/FI3830085T3/fi active
- 2019-07-26 LT LTEP23201458.9T patent/LT4331584T/lt unknown
- 2019-07-26 SM SM20240053T patent/SMT202400053T1/it unknown
- 2019-07-26 ES ES23201458T patent/ES3014955T3/es active Active
- 2019-07-26 SI SI201930912T patent/SI4331584T1/sl unknown
- 2019-07-26 RS RS20240090A patent/RS65095B1/sr unknown
- 2019-07-26 SI SI201930700T patent/SI3830085T1/sl unknown
- 2019-07-26 HR HRP20240157TT patent/HRP20240157T1/hr unknown
- 2019-07-26 DK DK23201458.9T patent/DK4331584T3/da active
- 2019-07-26 DK DK19759658.8T patent/DK3830085T3/da active
- 2019-07-26 ES ES19759658T patent/ES2970597T3/es active Active
- 2019-07-26 PL PL23201458.9T patent/PL4331584T3/pl unknown
- 2019-07-26 MD MDE20240961T patent/MD4331584T2/ro unknown
- 2019-07-26 RS RS20250261A patent/RS66614B1/sr unknown
-
2024
- 2024-02-07 JP JP2024017170A patent/JP7637281B2/ja active Active
-
2025
- 2025-04-30 US US19/194,878 patent/US20250263406A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SMT202500113T1 (it) | Utilizzi terapeutici di derivati deuterati del lanifibranor | |
| SG11202104461XA (en) | Therapeutic methods | |
| ZA201805634B (en) | Conjugate of therapeutic enzymes | |
| IL271777A (en) | Preparations for intravenous administration of medical substances | |
| GB201804514D0 (en) | Treatment of pyroptosis | |
| IL292657A (en) | Therapeutic history of interleukin-22 | |
| ZA201906238B (en) | New therapeutical use of h3-ligands | |
| IL276592A (en) | History of Subtirum | |
| GB201805816D0 (en) | Therapeutic agents | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases | |
| SG11202106009TA (en) | Deuterated analogs of acetyl-leucine | |
| GB201804515D0 (en) | Treatment of necroptosis | |
| GB201700526D0 (en) | Therapeutic use | |
| IL289338A (en) | Therapeutic interactions of leucomethylthionine | |
| GB201816553D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB201816554D0 (en) | Novel compounds and therapeutic uses thereof | |
| IL283295A (en) | gli1 inhibitors as therapeutic agents | |
| ZA202104656B (en) | Deuterated forms and derivatives of volinanserin | |
| GB201804098D0 (en) | Novel compounds and therapeutic uses thereof | |
| GB201812861D0 (en) | Methods of administering therapy | |
| HK40054945A (en) | Deuterated analogs of acetyl-leucine | |
| GB201813071D0 (en) | Novel therapeutic use | |
| GB201819936D0 (en) | Therapeutic methods | |
| GB201714772D0 (en) | Dosage forms of therapeutic compounds | |
| GB201813783D0 (en) | Therapeutic compositions |